Conference Coverage

‘Hidden’ cognitive impairments in DMD may worsen outcomes


 

FROM AANEM 2023

Overcoming a significant barrier

The NIH Toolbox has a lot of potential to improve DMD care, according to Dianna Quan, MD, who is the incoming president of AANEM, and professor of neurology at the University of Colorado at Denver, Aurora. “There’s this huge problem in terms of getting people in to see neuropsychologists and having formal evaluations. I think that’s a huge barrier. If we have people able to access this toolkit, which is simple and easily and universally accessible, how wonderful is that? I think that will be a really great improvement on what’s going on right now. It allows people to easily screen for these cognitive disabilities and make sure that we address them,” Dr. Quan said in an interview.

Asked how the tool could specifically improve care, Dr. Quan suggested that the first step is to understand the contributing factors to cognitive issues, whether they are biological, social, or a combination. “Some of them we can modify, potentially, through addressing the social environment. Some of those biologic factors may also be modifiable with many of the new drug studies that are coming.”

Dr. Thangarajh has received speaker honoraria from NS Pharma and PTC Therapeutics. Dr. Quan has received funding from Alnylam, Pfizer, Cytokinetics, Momenta, and Argenx.

Pages

Recommended Reading

Spinal muscular atrophy: Patient care in the age of genetically targeted therapy
MDedge Pediatrics
Novel gene-based therapies for neuromuscular diseases
MDedge Pediatrics
Children with autism show distinct brain features related to motor impairment
MDedge Pediatrics
AAP issues clinical update to cerebral palsy guidelines
MDedge Pediatrics
Three wild technologies about to change health care
MDedge Pediatrics
What’s new in brain health?
MDedge Pediatrics
Physician pleads guilty to 52 counts in opioid scheme
MDedge Pediatrics
Childhood trauma tied to increased Parkinson’s disease severity
MDedge Pediatrics
FDA okays drug for Duchenne muscular dystrophy
MDedge Pediatrics
Duchenne muscular dystrophy gene therapy safe, effective at 4 years
MDedge Pediatrics